Qube Research & Technologies LTD Blueprint Medicines Corp Call Options Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BPMC
# of Institutions
346Shares Held
62.5MCall Options Held
987KPut Options Held
578K-
Black Rock Inc. New York, NY6.65MShares$642 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.54MShares$632 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.87MShares$567 Million0.08% of portfolio
-
Wellington Management Group LLP Boston, MA3.24MShares$313 Million0.06% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.46MShares$238 Million8.22% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.77B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...